Janssen Submits BLA to FDA Seeking Approval of Guselkumab for Treatment of Severe Plaque Psoriasis (JNJ)
Go back to Janssen Submits BLA to FDA Seeking Approval of Guselkumab for Treatment of Severe Plaque Psoriasis (JNJ)| Johnson & Johnson (NYSE: JNJ) | Delayed: 148.53 -1.03 (0.69%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $149.56 | 52 Week High | $126.07 | |||
| Open | $148.14 | 52 Week Low | $94.28 | |||
| Day High | $148.99 | P/E | 30.88 | |||
| Day Low | $146.86 | EPS | $4.81 | |||
| Volume | 9,756,299 | |||||
